About PetMedix
PetMedix is a Healthcare company based in Babraham (United Kingdom) founded in 2017 by Thomas Weaver, and was acquired by Zoetis in September 2023. Developer of monoclonal antibody therapeutics for pets. PetMedix has raised $47.46 million across 3 funding rounds from investors including Tencent, Zoetis and Parkwalk. The company has 44 employees. Its chief executive, as recorded, is Thomas Weaver. Its focus areas include HealthTech, Veterinary HealthTech, Biopharmaceuticals and Diversified. Its legal entity is PETMEDIX LTD.
Company details
PetMedix was founded in 2017 in Babraham, United Kingdom, within the biotechnology sector focused on veterinary medicine. Monoclonal antibody therapeutics for pets are developed to address cancer, inflammation, and other conditions. The Ky9 and Felyne platforms are utilized to generate these antibodies, supporting operations in therapeutic innovation for animal health. Leadership includes co-founder Thomas Weaver as CEO.
- Headquarters Babraham, United Kingdom
- Employees 44
- Founders Thomas Weaver
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website petmedix.com
- Social LinkedIn X Facebook
- Acquired by Zoetis (Sep 2023)
- Legal Name Petmedix Ltd
- Date of Incorporation 05 Dec, 2017
- Jurisdiction CAMBRIDGE, CAMBRIDGESHIRE, ENGLAND
Funding Insights of PetMedix
PetMedix has successfully raised a total of $47.46M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $37 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $47.46M
- Total Rounds 3
- Last Round Series B — $37M
- First Round $10.46M
(Feb 2019)
- Investors Count 5
All 3 funding rounds of PetMedix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2021 | $37M | Series B | – | Parkwalk | |
| May 2020 | Series A | – | Cambridge Innovation Capital | – | |
| Feb 2019 | $10.46M | Series A | – | Digitalis Ventures |
6 investors in total: 6 institutional.
Investors in PetMedix
PetMedix has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Tencent, Zoetis and Parkwalk.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Tech companies are invested in by Parkwalk venture capital firm. | parkwalkadvisors.com | London, United Kingdom | ||
Digitalis Ventures is engaged in health-focused investments. | digitalisventures.com | New York, United States | ||
Venture capital investments are made in life sciences and deep tech. | 2013 | cic.vc | Cambridge, United Kingdom | |
Value-added internet, mobile, and telecom services are provided in China. | 1998 | tencent.com | Shenzhen, China | |
Musical instruments and accessories are distributed by Kyoritsu Corporation. | kyoritsu-group.com | Tokyo, Japan | ||
Animal medicines, vaccines, and diagnostics are manufactured and supplied. | 2012 | zoetis.com | Brussels, Belgium |
Investor details for PetMedix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of PetMedix
1 people are tracked at PetMedix (1 in leadership); the tracked headcount is 44.
| Name | Role | Group |
|---|---|---|
Thomas Weaver | Co-Founder & CEO | Leadership |
Complete people profiles for PetMedix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of PetMedix
4 dated milestones of PetMedix across 6 years, from founding to its latest funding, stage changes and deals.
- Founded PetMedix is founded.
- Funding First funding round of $10.5M.
- Funding Latest funding round, Series B, of $37.0M.
- Exit Acquired by Zoetis.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Petmedix
Complete news archive for PetMedix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PetMedix
PetMedix was founded in 2017 and raised its 1st funding round 2 years after it was founded.
PetMedix is headquartered in Babraham, United Kingdom. It is registered at Babraham, Cambridgeshire, United Kingdom.
Thomas Weaver is the CEO of PetMedix, as recorded in our data. They have also founded this company.
PetMedix is a funded company, having raised a total of $47.46M across 3 funding rounds to date. The company's 1st funding round was a Series A of $10.46M, raised on Feb 2019.
PetMedix has 44 employees.
PetMedix was founded in 2017 in Babraham, United Kingdom, within the biotechnology sector focused on veterinary medicine. Monoclonal antibody therapeutics for pets are developed to address cancer, inflammation, and other conditions. The Ky9 and Felyne platforms are utilized to generate these antibodies, supporting operations in therapeutic innovation for animal health. Leadership includes co-founder Thomas Weaver as CEO.
PetMedix has 6 investors. Key investors include Tencent, Zoetis, Parkwalk, Digitalis Ventures, and Cambridge Innovation Capital.
PetMedix operates through Petmedix Ltd.
Yes. PetMedix was acquired by Zoetis in September 2023.